Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KI5R
|
|||
| Drug Name |
Dabigatran etexilate
|
|||
| Synonyms |
BIBR-1048; 211915-06-9; Dabigatran etexilate mesilate; ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Dabigatran etexilate methanesulfonate; BIBR-1048 (Dabigatran); UNII-2E18WX195X; BIBR1048; BIBR-1048-BS-RS1; CHEBI:70746; 2E18WX195X; cc-72; DSSTox_CID_31470; DSSTox_RID_97355; DSSTox_GSID_57681; SCHEMBL505829; DTXSID4057681; Dabigatran etexilate (USAN/INN); MolPort-016-633-287; EBD35035; Tox21_113924; BDBM504
Click to Show/Hide
|
|||
| Indication | Venous thromboembolism [ICD-11: BD72; ICD-9: 453] | Phase 3 | [1] | |
| Company |
Boehringer Ingelheim Ridgefield, CT
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C34H41N7O5
|
|||
| Canonical SMILES |
CCCCCCOC(=O)NC(=N)C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4
|
|||
| InChI |
1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
|
|||
| InChIKey |
KSGXQBZTULBEEQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 211915-06-9
|
|||
| PubChem Compound ID | ||||
| ADReCS Drug ID | BADD_D00564 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.